This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Rate Control in Atrial Fibrillation

This study has been completed.
Information provided by (Responsible Party):
Tehran University of Medical Sciences Identifier:
First received: July 30, 2012
Last updated: NA
Last verified: July 2012
History: No changes posted

Rate control in atrial fibrillation is a usual battle in emergency departments. Oral medications have a natural superiority to intravenous ones because they are easy-to-use and decrease the workload in busy emergency departments.

This study wants to find an effective oral medication for rate control in rapid ventricular response atrial fibrillation. Propranolol and Metoprolol, Diltiazem and Verapamil are compared in patients with a stable hemodynamic status.

Condition Intervention Phase
Rapid Ventricular Response Atrial Fibrillation Drug: Propranolol Drug: Metoprolol Drug: Verapamil Drug: Diltiazem Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: Oral Propranolol, Diltiazem, Metoprolol and Verapamil in Atrial Fibrillation Rate Control in Patients With Stable Hemodynamic Status

Resource links provided by NLM:

Further study details as provided by Tehran University of Medical Sciences:

Primary Outcome Measures:
  • Rate less than 100 per minute [ Time Frame: In 1 hour ]
    Ventricular rate less than 100 per minute after 1 hour of per oral medication administration

Secondary Outcome Measures:
  • Drugs adverse effects [ Time Frame: 2 hours ]
    Drugs adverse effects seen in patients in 2 hours after per oral medication administration

  • Unstability in hemodynamic [ Time Frame: 2 hours ]
    Hemodynamic instability (systolic blood pressure less than 90 mmHg, loss of consciousness, pulmonary edema, chest pain)

Enrollment: 90
Study Start Date: February 2011
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Metoprolol Per Oral
50 mg Metoprolol
Drug: Metoprolol
Other Name: Metoral
Experimental: Verapamil
40 mg Verapamil Per Oral
Drug: Verapamil
Experimental: Propranolol
40 mg Propranolol Per Oral
Drug: Propranolol
Other Name: Inderal
Experimental: Diltiazem
60 mg Diltiazem Per Oral
Drug: Diltiazem


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age more than 18 years old
  • Stability in hemodynamic

Exclusion Criteria:

  • Systolic blood pressure less than 90 mm Hg
  • Altered mental status attributable to rapid ventricular response atrial fibrillation
  • Acute pulmonary edema attributable to rapid ventricular response atrial fibrillation
  • Chest pain attributable to rapid ventricular response atrial fibrillation
  • Allergy to Propranolol or Metoprolol or Verapamil or Diltiazem
  • History of asthma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01655303

Iran, Islamic Republic of
Rasoul-e-Akram Hospital
Tehran, Iran, Islamic Republic of, 14436151
Sponsors and Collaborators
Tehran University of Medical Sciences
  More Information

Responsible Party: Tehran University of Medical Sciences Identifier: NCT01655303     History of Changes
Other Study ID Numbers: 16057
Study First Received: July 30, 2012
Last Updated: July 30, 2012

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Vasodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic beta-1 Receptor Antagonists
Calcium Channel Blockers
Membrane Transport Modulators processed this record on September 21, 2017